Share ownership GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:18 2025-12-12 am EST			5-day change	1st Jan Change
1,824.50 ^GBX	+0.19%		+1.08%	+35.50%

Dec. 12	US FDA approves Innoviva's oral antibiotic for gonorrhea	RE
Dec. 12	Surprise UK GDP Contraction Keeps FTSE 100 in the Red	MT

Share class: GSK plc

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,315,116,636	4,078,489,304 ( 94.52 %)	169,171,155 ( 3.92 %)	94.52 %

Major shareholders: GSK plc

Name	Equities	%	Valuation
The Vanguard Group, Inc. 2.79 %	113,826,175	2.79 %	2 701 M p
Dodge & Cox 2.436 %	99,377,874	2.436 %	2 358 M p
Schroder Investment Management Ltd. 1.905 %	77,701,478	1.905 %	1 844 M p
Wellington Management Co. LLP 1.795 %	73,242,409	1.795 %	1 738 M p
BlackRock Advisors (UK) Ltd. 1.771 %	72,259,940	1.771 %	1 715 M p
Norges Bank Investment Management 1.611 %	65,735,000	1.611 %	1 560 M p
BlackRock Fund Advisors 1.596 %	65,098,999	1.596 %	1 545 M p
Legal & General Investment Management Ltd. 1.382 %	56,394,282	1.382 %	1 338 M p
SSgA Funds Management, Inc. 1.188 %	48,474,374	1.188 %	1 150 M p
Vanguard Global Advisers LLC 1.094 %	44,629,637	1.094 %	1 059 M p
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Dodge & Cox 3.844 %	78,403,734	3.844 %	3 752 M p
Fidelity Management & Research Co. LLC 3.243 %	66,143,500	3.243 %	3 166 M p
Fisher Asset Management LLC 1.58 %	32,227,615	1.58 %	1 542 M p
PRIMECAP Management Co. 1.263 %	25,766,950	1.263 %	1 233 M p
JTC Employer Solutions Trustee Ltd. 0.7156 %	14,597,185	0.7156 %	699 M p
RBC Private Counsel (USA), Inc. 0.5891 %	12,017,008	0.5891 %	575 M p
T. Rowe Price International Ltd. 0.3899 %	7,952,012	0.3899 %	381 M p
Holocene Advisors, LP 0.3481 %	7,100,420	0.3481 %	340 M p
STATE STREET CORPORATION 0.3246 %	6,621,951	0.3246 %	317 M p
Goldman Sachs Wealth Services LP 0.3196 %	6,518,931	0.3196 %	312 M p
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	60.32%
Other	4.13%
Individuals	0.34%
State Street Corp.	0.16%
Manulife Financial Corp.	0.1%
Governments	0.03%
SEI Investments Co.	0.02%
Cullen/Frost Bankers, Inc.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Credito Emiliano SpA	0.01%
Unknown	34.87%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	29.09%
United Kingdom	21.62%
Norway	1.81%
Switzerland	1.81%
Germany	1.69%
Canada	1.33%
Netherlands	0.94%
France	0.79%
Italy	0.7%
Japan	0.65%
Australia	0.57%
Sweden	0.51%
Spain	0.43%
Denmark	0.4%
Singapore	0.39%
Ireland	0.39%
Luxembourg	0.36%
Individuals	0.34%
South Korea	0.31%
Hong Kong	0.25%
Belgium	0.21%
Finland	0.16%
South Africa	0.11%
Austria	0.11%
New Zealand	0.03%
Kazakhstan	0.03%
Bahamas	0.02%
United Arab Emirates	0.01%
Liechtenstein	0.01%
Puerto Rico	0.01%
Pakistan	0.01%
Mexico	0.01%
Thailand	0.01%
Israel	0.01%

Based on 1000 largest holdings

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

Calendar

Jan. 12 - J.P. Morgan Healthcare Conference

More about the company